Intelligent Pills Market Report 2026

The intelligent pills market size has grown rapidly in recent years. It will grow from $4.66 billion in 2025 to $5.29 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to advances in medical imaging, gastrointestinal disease diagnosis demand, minimally invasive diagnostics growth, hospital technology adoption, wireless sensor innovation.

The intelligent pills market size is expected to see rapid growth in the next few years. It will grow to $8.65 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to remote healthcare expansion, AI-enabled diagnostics, digital health ecosystem growth, chronic disease monitoring needs, smart medical device innovation. Major trends in the forecast period include growing use of capsule endoscopy technologies, increased adoption of ingestible sensors, expansion of remote patient monitoring applications, rising demand for non-invasive diagnostic tools, integration of wireless data transmission in diagnostics.

The rising prevalence of lifestyle-related disorders is expected to drive growth in the intelligent pills market in the coming years. Lifestyle-related disorders are non-communicable diseases largely influenced by daily habits, behaviors, and choices. This increase is primarily driven by poor dietary habits, which contribute to obesity, heart disease, diabetes, and other chronic conditions. Intelligent pills support personalized treatment for lifestyle-related disorders by providing real-time health monitoring, data-driven insights, improving medication adherence, and optimizing therapeutic outcomes. For example, according to the Office for Health Improvement and Disparities in May 2025, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64% in 2022-2023. Consequently, the growing incidence of lifestyle-related disorders is propelling growth in the intelligent pills market.

The increasing focus on personalized medicine is also expected to boost the intelligent pills market. Personalized medicine tailors prevention and treatment strategies to individual patient characteristics, such as genetics, biomarkers, and behavior. The emphasis on personalized medicine is rising due to advances in genomics, better understanding of individual variability in disease and treatment response, and the ability to tailor therapies to each patient’s unique genetic, environmental, and lifestyle factors. Intelligent pills enable personalized medicine by delivering smart, data-driven dosing and monitoring that adjusts therapy in real time according to an individual’s physiology. For instance, according to the Personalized Medicine Coalition in February 2024, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing focus on personalized medicine is driving growth in the intelligent pills market.

Leading companies in the intelligent pills market are leveraging innovative technologies, such as wearable ingestion tracking devices, to improve medication adherence and patient monitoring. Wearable ingestion tracking devices are wrist-worn or body-mounted tools that monitor when patients take their medication, ensuring timely doses, improving adherence, and providing real-time data to healthcare providers for better treatment outcomes. For example, in November 2023, etectRx Inc., a US-based digital health company, launched the Wrist-Worn Reader, enhancing the ID-Cap System. This device offers a convenient wrist-worn format instead of the previous necklace-style reader, increasing comfort and usability. The Wrist-Worn Reader continuously records ingestion events, provides alerts for missed doses, and supports clinical studies such as HIV PrEP trials, thereby improving adherence and patient outcomes. Its adaptability to diverse lifestyles and user preferences distinguishes it from conventional monitoring solutions.

Major companies operating in the intelligent pills market are RF Co. Ltd., OMOMED S.A., Shangxian Minimal Invasive Inc., Medtronic Given Imaging (PillCam Division), Shenzhen ANX Robotica, Capsovision Europe GmbH, BDD (Bio-Medical Device Development Ltd.), SmartPill Corporation, ReX Medical, Sensilize Ltd., HQ Inc., JIFU Medical, Chongqing Jinshan Capsule Endoscopy, CapsoVision Asia, NaviCam Medical Systems, IntroMedic Europe, EBS Medical, Check-Cap Imaging, Biora Therapeutics, etectRx Digital Health.

North America was the largest region in the intelligent pills market in 2025. The regions covered in the intelligent pills market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intelligent pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have significantly affected the intelligent pills market by increasing the cost of electronic sensors, microchips, wireless transmitters, and pharmaceutical-grade capsule materials required for smart pill manufacturing. Capsule endoscopy and patient-monitoring applications are most impacted, especially in Asia-Pacific and North America where semiconductor and medical device imports are heavily used. Hospitals, clinics, and research institutes face higher device procurement costs. Positively, tariffs are encouraging regional electronics integration and local assembly of smart medical devices, improving technological self-sufficiency.

The intelligent pills market research report is one of a series of new reports that provides intelligent pills market statistics, including intelligent pills industry global market size, regional shares, competitors with a intelligent pills market share, detailed intelligent pills market segments, market trends and opportunities, and any further data you may need to thrive in the intelligent pills industry. This intelligent pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intelligent pills, also called smart pills, are ingestible devices equipped with sensors and wireless technology to monitor and transmit data from inside the body. They are used for medical purposes, including tracking patient compliance, diagnosing conditions, and delivering precise drug treatments.

The main types of intelligent pills include those for occult GI bleeding, Crohn’s disease, small bowel tumors, celiac disease, inherited polyposis syndromes, and neurological disorders. Occult gastrointestinal (GI) bleeding refers to hidden or undetectable bleeding in the digestive tract, usually detected through tests rather than visible symptoms. These pills target areas such as the esophagus, stomach, small intestine, and large intestine. They are applied in capsule endoscopy, drug delivery, and patient monitoring, and are used by hospitals, clinics, research institutes, and home healthcare providers.

The intelligent pills market consists of revenues earned by entities by providing services such as patient and treatment management, brainstorm-as-a-service, precision pitch crafting, and cyber health checks. The market value includes the value of related goods sold by the service provider or included within the service offering. The intelligent pills market also includes sales of ingestible sensors, pH-sensitive capsules, temperature-monitoring pills, targeted drug delivery capsules, and capsules with wireless communication capabilities. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.